CoChat
Sign Up
Cited by 13Mesenchymal stem cell researchHematopoietic Stem Cell TransplantationAcute Myeloid Leukemia Research

Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia

Open access
Wu, Cheng-Hsien, Weng, Te-Fu, Li, Ju-Pi, Wu, Kang-Hsi·2024·International Journal of Molecular Sciences
DOI 10.3390/ijms25052527PMC PMC10932140
Open this paper in CoChat — free accountOpen PDF

Abstract

This comprehensive review delves into the multifaceted roles of mesenchymal stem cells (MSCs) in leukemia, focusing on their interactions within the bone marrow microenvironment and their impact on leukemia pathogenesis, progression, and treatment resistance. MSCs, characterized by their ability to differentiate into various cell types and modulate the immune system, are integral to the BM niche, influencing hematopoietic stem cell maintenance and functionality. This review extensively explores the intricate relationship between MSCs and leukemic cells in acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia. This review also addresses the potential clinical applications of MSCs in leukemia treatment. MSCs’ role in hematopoietic stem cell transplantation, their antitumor effects, and strategies to disrupt chemo-resistance are discussed. Despite their therapeutic potential, the dual nature of MSCs in promoting and inhibiting tumor growth poses significant challenges. Further research is needed to understand MSCs’ biological mechanisms in hematologic malignancies and develop targeted therapeutic strategies. This in-depth exploration of MSCs in leukemia provides crucial insights for advancing treatment modalities and improving patient outcomes in hematologic malignancies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms25052527

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mesenchymal stromal cells may unintentionally facilitate tumor progression, especially in hematologic malignancies such as multiple myeloma.

    “Multiple studies have shown that MSCs may unintentionally facilitate tumor progression, especially in hematologic malignancies such as MM, where the bone marrow microenvironment is already affected by cancerous plasma cells.”

    From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [297]

    The Conclusions (section 10; page unavailable) say MSCs can aid tumor blood vessel formation, metastasis, relapse, and chemotherapy resistance in hematologic malignancies. The paper does not establish this specifically for multiple myeloma or describe a bone marrow microenvironment affected by cancerous plasma cells; its only exact mention of multiple myeloma is in a reference to a treatment study. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • Interactions between mesenchymal stromal cells and malignant plasma cells in multiple myeloma can create a more supportive tumor microenvironment, potentially complicating treatment outcomes and disease prognosis.

    “The interactions between mesenchymal stem cells and malignant plasma cells in multiple myeloma can create a more supportive tumor microenvironment, potentially complicating treatment outcomes and disease prognosis [297].”

    From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [297]

    Section 8.1 (MSCs in CLL Progression; page unavailable) says interactions between mesenchymal stem cells and CLL cells create a supportive microenvironment and can influence treatment responses. The Conclusions (page unavailable) also discuss MSC-mediated drug resistance in hematologic malignancies. Neither passage establishes the claim specifically for malignant plasma cells in multiple myeloma, so the disease-specific attribution is unsupported. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 214

  1. [1]Uccelli A. Moretta L. Pistoia V. Mesenchymal stem cells in health and disease Nat. Rev. Immunol. 2008 8 726 736 10.1038/nri2395 19172693 · DOI
  2. [2]Horwitz E.M. Le Blanc K. Dominici M. Mueller I. Slaper-Cortenbach I. Marini F.C. Deans R.J. Krause D.S. Keating A. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement Cytotherapy 2005 7 393 395 10.1080/14653240500319234 16236628 · DOI
  3. [3]Dominici M. Le Blanc K. Mueller I. Slaper-Cortenbach I. Marini F. Krause D. Deans R. Keating A. Prockop D. Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy 2006 8 315 317 10.1080/14653240600855905 16923606 · DOI · Paper page
  4. [4]Ullah I. Subbarao R.B. Rho G.J. Human mesenchymal stem cells-current trends and future prospective Biosci. Rep. 2015 35 e00191 10.1042/BSR20150025 25797907 PMC4413017 · DOI
  5. [5]Asada N. Takeishi S. Frenette P.S. Complexity of bone marrow hematopoietic stem cell niche Int. J. Hematol. 2017 106 45 54 10.1007/s12185-017-2262-9 28534115 PMC8808638 · DOI
  6. [6]Kfoury Y. Scadden D.T. Mesenchymal cell contributions to the stem cell niche Cell Stem Cell 2015 16 239 253 10.1016/j.stem.2015.02.019 25748931 · DOI
  7. [7]Wei Q. Frenette P.S. Niches for Hematopoietic Stem Cells and Their Progeny Immunity 2018 48 632 648 10.1016/j.immuni.2018.03.024 29669248 PMC6103525 · DOI
  8. [8]Barthes J. Özçelik H. Hindié M. Ndreu-Halili A. Hasan A. Vrana N.E. Cell microenvironment engineering and monitoring for tissue engineering and regenerative medicine: The recent advances Biomed. Res. Int. 2014 2014 921905 10.1155/2014/921905 25143954 PMC4124711 · DOI
  9. [9]Liu J. Gao J. Liang Z. Gao C. Niu Q. Wu F. Zhang L. Mesenchymal stem cells and their microenvironment Stem Cell Res. Ther. 2022 13 429 10.1186/s13287-022-02985-y 35987711 PMC9391632 · DOI
  10. [10]Birbrair A. Frenette P.S. Niche heterogeneity in the bone marrow Ann. N. Y. Acad. Sci. 2016 1370 82 96 10.1111/nyas.13016 27015419 PMC4938003 · DOI
  11. [11]Tan L. Liu X. Dou H. Hou Y. Characteristics and regulation of mesenchymal stem cell plasticity by the microenvironment-specific factors involved in the regulation of MSC plasticity Genes. Dis. 2022 9 296 309 10.1016/j.gendis.2020.10.006 35224147 PMC8843883 · DOI
  12. [12]Peta K.T. Ambele M.A. Pepper M.S. Similarities between Tumour Immune Response and Chronic Wound Microenvironment: Influence of Mesenchymal Stromal/Stem Cells J. Immunol. Res. 2021 2021 6649314 10.1155/2021/6649314 33860061 PMC8024060 · DOI
  13. [13]Belson M. Kingsley B. Holmes A. Risk factors for acute leukemia in children: A review Environ. Health Perspect. 2007 115 138 145 10.1289/ehp.9023 17366834 PMC1817663 · DOI
  14. [14]Zhou H.S. Carter B.Z. Andreeff M. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang Cancer Biol. Med. 2016 13 248 259 10.20892/j.issn.2095-3941.2016.0023 27458532 PMC4944541 · DOI
  15. [15]Buss E.C. Ho A.D. Leukemia stem cells Int. J. Cancer 2011 129 2328 2336 10.1002/ijc.26318 21796620 · DOI
  16. [16]Yao J.C. Link D.C. Concise Review: The Malignant Hematopoietic Stem Cell Niche Stem Cells 2017 35 3 8 10.1002/stem.2487 27647718 · DOI
  17. [17]Colmone A. Amorim M. Pontier A.L. Wang S. Jablonski E. Sipkins D.A. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells Science 2008 322 1861 1865 10.1126/science.1164390 19095944 · DOI
  18. [18]Arber D.A. Orazi A. Hasserjian R. Thiele J. Borowitz M.J. Le Beau M.M. Bloomfield C.D. Cazzola M. Vardiman J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 2016 127 2391 2405 10.1182/blood-2016-03-643544 27069254 · DOI · Paper page
  19. [19]Brunning R.D. Classification of acute leukemias Semin. Diagn. Pathol. 2003 20 142 153 10.1016/S0740-2570(03)00031-5 14552428 · DOI
  20. [20]Vardiman J.W. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: An overview with emphasis on the myeloid neoplasms Chem. Biol. Interact. 2010 184 16 20 10.1016/j.cbi.2009.10.009 19857474 · DOI
  21. [21]Belyavsky A.V. Niches of Hematopoietic Stem Cells in Bone Marrow Mol. Biol. 2019 53 1012 1019 10.1134/S0026893319060025 31876279 · DOI
  22. [22]Kandarakov O. Belyavsky A. Semenova E. Bone Marrow Niches of Hematopoietic Stem and Progenitor Cells Int. J. Mol. Sci. 2022 23 4462 10.3390/ijms23084462 35457280 PMC9032554 · DOI
  23. [23]Lee-Thedieck C. Schertl P. Klein G. The extracellular matrix of hematopoietic stem cell niches Adv. Drug Deliv. Rev. 2022 181 114069 10.1016/j.addr.2021.114069 34838648 PMC8860232 · DOI
  24. [24]Cominal J.G. da Costa Cacemiro M. Pinto-Simões B. Kolb H.J. Malmegrim K.C.R. de Castro F.A. Emerging Role of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Pathogenesis of Haematological Malignancies Stem Cells Int. 2019 2019 6854080 10.1155/2019/6854080 31281380 PMC6589251 · DOI
  25. [25]Pittenger M.F. Mackay A.M. Beck S.C. Jaiswal R.K. Douglas R. Mosca J.D. Moorman M.A. Simonetti D.W. Craig S. Marshak D.R. Multilineage potential of adult human mesenchymal stem cells Science 1999 284 143 147 10.1126/science.284.5411.143 10102814 · DOI · Paper page
  26. [26]Simmons P.J. Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1 Blood 1991 78 55 62 10.1182/blood.V78.1.55.55 2070060 · DOI
  27. [27]Kuçi S. Kuçi Z. Kreyenberg H. Deak E. Pütsch K. Huenecke S. Amara C. Koller S. Rettinger E. Grez M. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties Haematologica 2010 95 651 659 10.3324/haematol.2009.015065 20179086 PMC2857196 · DOI
  28. [28]Méndez-Ferrer S. Michurina T.V. Ferraro F. Mazloom A.R. Macarthur B.D. Lira S.A. Scadden D.T. Ma’ayan A. Enikolopov G.N. Frenette P.S. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche Nature 2010 466 829 834 10.1038/nature09262 20703299 PMC3146551 · DOI
  29. [29]Sacchetti B. Funari A. Michienzi S. Di Cesare S. Piersanti S. Saggio I. Tagliafico E. Ferrari S. Robey P.G. Riminucci M. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment Cell 2007 131 324 336 10.1016/j.cell.2007.08.025 17956733 · DOI · Paper page
  30. [30]Sugiyama T. Kohara H. Noda M. Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches Immunity 2006 25 977 988 10.1016/j.immuni.2006.10.016 17174120 · DOI
  31. [31]Boulais P.E. Frenette P.S. Making sense of hematopoietic stem cell niches Blood 2015 125 2621 2629 10.1182/blood-2014-09-570192 25762174 PMC4408288 · DOI
  32. [32]Crippa S. Bernardo M.E. Mesenchymal Stromal Cells: Role in the BM Niche and in the Support of Hematopoietic Stem Cell Transplantation Hemasphere 2018 2 e151 10.1097/HS9.0000000000000151 31723790 PMC6745957 · DOI
  33. [33]Ehninger A. Trumpp A. The bone marrow stem cell niche grows up: Mesenchymal stem cells and macrophages move in J. Exp. Med. 2011 208 421 428 10.1084/jem.20110132 21402747 PMC3058583 · DOI
  34. [34]Pontikoglou C. Deschaseaux F. Sensebé L. Papadaki H.A. Bone marrow mesenchymal stem cells: Biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation Stem Cell Rev. Rep. 2011 7 569 589 10.1007/s12015-011-9228-8 21249477 · DOI
  35. [35]Taichman R.S. Blood and bone: Two tissues whose fates are intertwined to create the hematopoietic stem-cell niche Blood 2005 105 2631 2639 10.1182/blood-2004-06-2480 15585658 · DOI
  36. [36]Taichman R.S. Emerson S.G. The role of osteoblasts in the hematopoietic microenvironment Stem Cells 1998 16 7 15 10.1002/stem.160007 9474743 · DOI
  37. [37]Zhi W. Deng L. Yang Z. Role of osteoblasts in the hematopoietic microenvironment of bone marrow and regulatory pathways and mechanisms Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2007 21 517 522 17578294
  38. [38]Taichman R.S. Emerson S.G. Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor J. Exp. Med. 1994 179 1677 1682 10.1084/jem.179.5.1677 7513014 PMC2191506 · DOI
  39. [39]Visnjic D. Kalajzic Z. Rowe D.W. Katavic V. Lorenzo J. Aguila H.L. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency Blood 2004 103 3258 3264 10.1182/blood-2003-11-4011 14726388 · DOI
  40. [40]Zhu J. Garrett R. Jung Y. Zhang Y. Kim N. Wang J. Joe G.J. Hexner E. Choi Y. Taichman R.S. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells Blood 2007 109 3706 3712 10.1182/blood-2006-08-041384 17227831 · DOI
  41. [41]Batsali A.K. Georgopoulou A. Mavroudi I. Matheakakis A. Pontikoglou C.G. Papadaki H.A. The Role of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles (MSC-EVs) in Normal and Abnormal Hematopoiesis and Their Therapeutic Potential J. Clin. Med. 2020 9 856 10.3390/jcm9030856 32245055 PMC7141498 · DOI
  42. [43]Cocucci E. Meldolesi J. Ectosomes and exosomes: Shedding the confusion between extracellular vesicles Trends Cell Biol. 2015 25 364 372 10.1016/j.tcb.2015.01.004 25683921 · DOI · Paper page
  43. [44]Colombo M. Raposo G. Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles Annu. Rev. Cell Dev. Biol. 2014 30 255 289 10.1146/annurev-cellbio-101512-122326 25288114 · DOI · Paper page
  44. [45]Melzer C. Yang Y. Hass R. Interaction of MSC with tumor cells Cell Commun. Signal 2016 14 20 10.1186/s12964-016-0143-0 27608835 PMC5016940 · DOI
  45. [46]Butler J.T. Abdelhamed S. Kurre P. Extracellular vesicles in the hematopoietic microenvironment Haematologica 2018 103 382 394 10.3324/haematol.2017.183335 29439185 PMC5830368 · DOI
  46. [47]Timari H. Shamsasenjan K. Movassaghpour A. Akbarzadehlaleh P. Pashoutan Sarvar D. Aqmasheh S. The Effect of Mesenchymal Stem Cell-Derived Extracellular Vesicles on Hematopoietic Stem Cells Fate Adv. Pharm. Bull. 2017 7 531 546 10.15171/apb.2017.065 29399543 PMC5788208 · DOI
  47. [49]Seo Y. Kim H.S. Hong I.S. Stem Cell-Derived Extracellular Vesicles as Immunomodulatory Therapeutics Stem Cells Int. 2019 2019 5126156 10.1155/2019/5126156 30936922 PMC6413386 · DOI
  48. [50]Park K.S. Bandeira E. Shelke G.V. Lässer C. Lötvall J. Enhancement of therapeutic potential of mesenchymal stem cell-derived extracellular vesicles Stem Cell Res. Ther. 2019 10 288 10.1186/s13287-019-1398-3 31547882 PMC6757418 · DOI
  49. [51]Gong M. Yu B. Wang J. Wang Y. Liu M. Paul C. Millard R.W. Xiao D.S. Ashraf M. Xu M. Mesenchymal stem cells release exosomes that transfer miRNAs to endothelial cells and promote angiogenesis Oncotarget 2017 8 45200 45212 10.18632/oncotarget.16778 28423355 PMC5542178 · DOI
  50. [52]De Kouchkovsky I. Abdul-Hay M. Acute myeloid leukemia: A comprehensive review and 2016 update Blood Cancer J. 2016 6 e441 10.1038/bcj.2016.50 27367478 PMC5030376 · DOI
  51. [53]Guo Y. Wang W. Sun H. A systematic review and meta-analysis on the risk factors of acute myeloid leukemia Transl. Cancer Res. 2022 11 796 804 10.21037/tcr-22-27 35571664 PMC9091028 · DOI
  52. [54]Hartmann L. Metzeler K.H. Clonal hematopoiesis and preleukemia-Genetics, biology, and clinical implications Genes. Chromosomes Cancer 2019 58 828 838 10.1002/gcc.22756 30939217 · DOI
  53. [55]Kosmidou A. Tragiannidis A. Gavriilaki E. Myeloid Leukemia of Down Syndrome Cancers 2023 15 3265 10.3390/cancers15133265 37444375 PMC10340042 · DOI
  54. [56]Thirman M.J. Larson R.A. Therapy-related myeloid leukemia Hematol. Oncol. Clin. N. Am. 1996 10 293 320 10.1016/S0889-8588(05)70340-3 8707757 · DOI
  55. [57]Ley T.J. Miller C. Ding L. Raphael B.J. Mungall A.J. Robertson A. Hoadley K. Triche T.J. Jr. Laird P.W. Baty J.D. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia N. Engl. J. Med. 2013 368 2059 2074 23634996 PMC3767041
  56. [59]Moarii M. Papaemmanuil E. Classification and risk assessment in AML: Integrating cytogenetics and molecular profiling Hematology Am. Soc. Hematol. Educ. Program. 2017 2017 37 44 10.1182/asheducation-2017.1.37 29222235 PMC6142605 · DOI
  57. [60]Diaz de la Guardia R. Lopez-Millan B. Lavoie J.R. Bueno C. Castaño J. Gómez-Casares M. Vives S. Palomo L. Juan M. Delgado J. Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes Stem Cell Rep. 2017 8 1573 1586 10.1016/j.stemcr.2017.04.019 PMC5470078 28528702 · DOI
  58. [61]Fracchiolla N.S. Fattizzo B. Cortelezzi A. Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications Stem Cells Int. 2017 2017 6720594 10.1155/2017/6720594 28947904 PMC5602646 · DOI
  59. [62]Brenner A.K. Nepstad I. Bruserud Ø. Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms Front. Immunol. 2017 8 106 10.3389/fimmu.2017.00106 28232835 PMC5299032 · DOI
  60. [63]Azadniv M. Myers J.R. McMurray H.R. Guo N. Rock P. Coppage M.L. Ashton J. Becker M.W. Calvi L.M. Liesveld J.L. Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support Leukemia 2020 34 391 403 10.1038/s41375-019-0568-8 31492897 PMC7214245 · DOI
  61. [64]Tan Z. Kan C. Wong M. Sun M. Liu Y. Yang F. Wang S. Zheng H. Regulation of Malignant Myeloid Leukemia by Mesenchymal Stem Cells Front. Cell Dev. Biol. 2022 10 857045 10.3389/fcell.2022.857045 35756991 PMC9213747 · DOI
  62. [65]Barrera-Ramirez J. Lavoie J.R. Maganti H.B. Stanford W.L. Ito C. Sabloff M. Brand M. Rosu-Myles M. Le Y. Allan D.S. Micro-RNA Profiling of Exosomes from Marrow-Derived Mesenchymal Stromal Cells in Patients with Acute Myeloid Leukemia: Implications in Leukemogenesis Stem Cell Rev. Rep. 2017 13 817 825 10.1007/s12015-017-9762-0 28918518 PMC5730624 · DOI
  63. [66]Wu J. Zhang Y. Li X. Ren J. Chen L. Chen J. Cao Y. Exosomes from bone marrow mesenchymal stem cells decrease chemosensitivity of acute myeloid leukemia cells via delivering miR-10a Biochem. Biophys. Res. Commun. 2022 622 149 156 10.1016/j.bbrc.2022.07.017 35863089 · DOI
  64. [67]Lu J. Dong Q. Zhang S. Feng Y. Yang J. Zhao L. Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling Cancer Sci. 2023 114 3287 3300 10.1111/cas.15855 37272257 PMC10394133 · DOI
  65. [68]Aggarwal S. Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses Blood 2005 105 1815 1822 10.1182/blood-2004-04-1559 15494428 · DOI · Paper page
  66. [69]Luciano M. Krenn P.W. Horejs-Hoeck J. The cytokine network in acute myeloid leukemia Front. Immunol. 2022 13 1000996 10.3389/fimmu.2022.1000996 36248849 PMC9554002 · DOI
  67. [70]Lee M.W. Ryu S. Kim D.S. Lee J.W. Sung K.W. Koo H.H. Yoo K.H. Mesenchymal stem cells in suppression or progression of hematologic malignancy: Current status and challenges Leukemia 2019 33 597 611 10.1038/s41375-018-0373-9 30705410 PMC6756083 · DOI
  68. [71]Lee H.Y. Hong I.S. Double-edged sword of mesenchymal stem cells: Cancer-promoting versus therapeutic potential Cancer Sci. 2017 108 1939 1946 10.1111/cas.13334 28756624 PMC5623746 · DOI
  69. [72]Yagi H. Kitagawa Y. The role of mesenchymal stem cells in cancer development Front. Genet. 2013 4 261 10.3389/fgene.2013.00261 24348516 PMC3842093 · DOI
  70. [73]Liang R. Huang G.S. Wang Z. Chen X.Q. Bai Q.X. Zhang Y.Q. Dong B.X. Wang W.Q. Effects of human bone marrow stromal cell line (HFCL) on the proliferation, differentiation and apoptosis of acute myeloid leukemia cell lines U937, HL-60 and HL-60/VCR Int. J. Hematol. 2008 87 152 166 10.1007/s12185-008-0030-6 18288567 · DOI
  71. [74]Fathi E. Farahzadi R. Valipour B. Sanaat Z. Cytokines secreted from bone marrow derived mesenchymal stem cells promote apoptosis and change cell cycle distribution of K562 cell line as clinical agent in cell transplantation PLoS ONE 2019 14 e0215678 10.1371/journal.pone.0215678 31009502 PMC6476492 · DOI
  72. [75]Phetfong J. Tawonsawatruk T. Kamprom W. Ontong P. Tanyong D. Borwornpinyo S. Supokawej A. Bone marrow-mesenchymal stem cell-derived extracellular vesicles affect proliferation and apoptosis of leukemia cells in vitro FEBS Open Bio 2022 12 470 479 10.1002/2211-5463.13352 PMC8804606 34907674 · DOI
  73. [76]Aravindhan S. Ejam S.S. Lafta M.H. Markov A. Yumashev A.V. Ahmadi M. Mesenchymal stem cells and cancer therapy: Insights into targeting the tumour vasculature Cancer Cell Int. 2021 21 158 10.1186/s12935-021-01836-9 33685452 PMC7938588 · DOI
  74. [77]Roberts K.G. Genetics and prognosis of ALL in children vs. adults Hematol. Am. Soc. Hematol. Educ. Program 2018 2018 137 145 10.1182/asheducation-2018.1.137 PMC6245970 30504302 · DOI
  75. [78]Terwilliger T. Abdul-Hay M. Acute lymphoblastic leukemia: A comprehensive review and 2017 update Blood Cancer J. 2017 7 e577 10.1038/bcj.2017.53 28665419 PMC5520400 · DOI
  76. [79]Tebbi C.K. Etiology of Acute Leukemia: A Review Cancers 2021 13 2256 10.3390/cancers13092256 34066700 PMC8125807 · DOI
  77. [80]Bhojwani D. Yang J.J. Pui C.H. Biology of childhood acute lymphoblastic leukemia Pediatr. Clin. N. Am. 2015 62 47 60 10.1016/j.pcl.2014.09.004 PMC4250840 25435111 · DOI
  78. [81]Kakaje A. Alhalabi M.M. Ghareeb A. Karam B. Mansour B. Zahra B. Hamdan O. Rates and trends of childhood acute lymphoblastic leukaemia: An epidemiology study Sci. Rep. 2020 10 6756 10.1038/s41598-020-63528-0 32317670 PMC7174306 · DOI
  79. [82]Yi M. Zhou L. Li A. Luo S. Wu K. Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017 Aging 2020 12 22869 22891 10.18632/aging.103982 33203796 PMC7746341 · DOI
  80. [83]Zhu W. Liu S. Shi Y. Tang Q. Sun J. Bai R. Sun Z. Du Z. The epidemic of acute lymphoid leukemia in China: Current trends and future prediction Front. Oncol. 2023 13 1195065 10.3389/fonc.2023.1195065 37397360 PMC10313194 · DOI
  81. [84]DeRenzo C. Krenciute G. Gottschalk S. The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors Am. Soc. Clin. Oncol. Educ. Book 2018 38 830 837 10.1200/EDBK_200773 30231350 PMC11613507 · DOI
  82. [85]Ramos K.N. Ramos I.N. Zeng Y. Ramos K.S. Genetics and epigenetics of pediatric leukemia in the era of precision medicine F1000Res 2018 7 F1000 10.12688/f1000research.14634.1 PMC6053694 30079227 · DOI
  83. [86]Valentin R. Grabow S. Davids M.S. The rise of apoptosis: Targeting apoptosis in hematologic malignancies Blood 2018 132 1248 1264 10.1182/blood-2018-02-791350 30012635 · DOI
  84. [87]Fallati A. Di Marzo N. D’Amico G. Dander E. Mesenchymal Stromal Cells (MSCs): An Ally of B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells in Disease Maintenance and Progression within the Bone Marrow Hematopoietic Niche Cancers 2022 14 3303 10.3390/cancers14143303 35884364 PMC9323332 · DOI
  85. [88]Tirado H.A. Balasundaram N. Laaouimir L. Erdem A. van Gastel N. Metabolic crosstalk between stromal and malignant cells in the bone marrow niche Bone Rep. 2023 18 101669 10.1016/j.bonr.2023.101669 36909665 PMC9996235 · DOI
  86. [89]Woods K. Guezguez B. Dynamic Changes of the Bone Marrow Niche: Mesenchymal Stromal Cells and Their Progeny during Aging and Leukemia Front. Cell Dev. Biol. 2021 9 714716 10.3389/fcell.2021.714716 34447754 PMC8383146 · DOI
  87. [90]Witkowski M.T. Dolgalev I. Evensen N.A. Ma C. Chambers T. Roberts K.G. Sreeram S. Dai Y. Tikhonova A.N. Lasry A. Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia Cancer Cell 2020 37 867 882.e12 10.1016/j.ccell.2020.04.015 32470390 PMC7341535 · DOI
  88. [91]Hughes A.M. Kuek V. Oommen J. Chua G.A. van Loenhout M. Malinge S. Kotecha R.S. Cheung L.C. Characterization of mesenchymal stem cells in pre-B acute lymphoblastic leukemia Front. Cell Dev. Biol. 2023 11 1005494 10.3389/fcell.2023.1005494 36743421 PMC9897315 · DOI
  89. [92]Chiu M. Taurino G. Bianchi M.G. Bussolati O. The Role of Amino Acids in the Crosstalk Between Mesenchymal Stromal Cells and Neoplastic Cells in the Hematopoietic Niche Front. Cell Dev. Biol. 2021 9 714755 10.3389/fcell.2021.714755 34277645 PMC8278102 · DOI
  90. [93]Chiu M. Taurino G. Dander E. Bardelli D. Fallati A. Andreoli R. Bianchi M.G. Carubbi C. Pozzi G. Galuppo L. ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment Blood Adv. 2021 5 5164 5178 10.1182/bloodadvances.2020004041 34614505 PMC9153005 · DOI
  91. [94]Polak R. de Rooij B. Pieters R. den Boer M.L. B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment Blood 2015 126 2404 2414 10.1182/blood-2015-03-634238 26297738 · DOI
  92. [95]De Rooij B. Polak R. Stalpers F. Pieters R. den Boer M.L. Tunneling nanotubes facilitate autophagosome transfer in the leukemic niche Leukemia 2017 31 1651 1654 10.1038/leu.2017.117 28400620 PMC5508073 · DOI
  93. [96]Burt R. Dey A. Aref S. Aguiar M. Akarca A. Bailey K. Day W. Hooper S. Kirkwood A. Kirschner K. Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress Blood 2019 134 1415 1429 10.1182/blood.2019001398 31501154 PMC6856969 · DOI
  94. [97]Kihira K. Chelakkot V.S. Kainuma H. Okumura Y. Tsuboya N. Okamura S. Kurihara K. Iwamoto S. Komada Y. Hori H. Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells Int. J. Hematol. 2020 112 795 806 10.1007/s12185-020-02981-z 32862292 · DOI
  95. [98]Manabe A. Coustan-Smith E. Behm F.G. Raimondi S.C. Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia Blood 1992 79 2370 2377 10.1182/blood.V79.9.2370.2370 1373973 · DOI
  96. [99]Jacamo R. Chen Y. Wang Z. Ma W. Zhang M. Spaeth E.L. Wang Y. Battula V.L. Mak P.Y. Schallmoser K. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance Blood 2014 123 2691 2702 10.1182/blood-2013-06-511527 24599548 PMC3999754 · DOI
  97. [100]Ma Z. Zhao X. Deng M. Huang Z. Wang J. Wu Y. Cui D. Liu Y. Liu R. Ouyang G. Bone Marrow Mesenchymal Stromal Cell-Derived Periostin Promotes B-ALL Progression by Modulating CCL2 in Leukemia Cells Cell Rep. 2019 26 1533 1543.e4 10.1016/j.celrep.2019.01.034 30726736 · DOI
  98. [101]Tian C. Li Y. Wang L. Si J. Zheng Y. Kang J. Wang Y. You M.J. Zheng G. Blockade of FGF2/FGFR2 partially overcomes bone marrow mesenchymal stromal cells mediated progression of T-cell acute lymphoblastic leukaemia Cell Death Dis. 2022 13 922 10.1038/s41419-022-05377-5 36333298 PMC9636388 · DOI
  99. [102]Cowell J.K. Qin H. Hu T. Wu Q. Bhole A. Ren M. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas Int. J. Cancer 2017 141 1822 1829 10.1002/ijc.30848 28646488 PMC5850950 · DOI
  100. [103]Hu T. Wu Q. Chong Y. Qin H. Poole C.J. van Riggelen J. Ren M. Cowell J.K. FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome Leukemia 2018 32 2363 2373 10.1038/s41375-018-0124-y 29720732 PMC6168426 · DOI
  101. [104]Chong Y. Liu Y. Lu S. Cai B. Qin H. Chang C.S. Ren M. Cowell J.K. Hu T. Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome Int. J. Cancer 2020 146 2243 2254 10.1002/ijc.32665 31525277 · DOI
  102. [105]Ramuta T. Kreft M.E. Mesenchymal Stem/Stromal Cells May Decrease Success of Cancer Treatment by Inducing Resistance to Chemotherapy in Cancer Cells Cancers 2022 14 3761 10.3390/cancers14153761 35954425 PMC9367361 · DOI
  103. [106]Wang J. Liu X. Qiu Y. Shi Y. Cai J. Wang B. Wei X. Ke Q. Sui X. Wang Y. Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells J. Hematol. Oncol. 2018 11 11 10.1186/s13045-018-0554-z 29357914 PMC5778754 · DOI
  104. [107]Cai J. Wang J. Huang Y. Wu H. Xia T. Xiao J. Chen X. Li H. Qiu Y. Wang Y. ERK/Drp1-dependent mitochondrial fission is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells Cell Death Dis. 2016 7 e2459 10.1038/cddis.2016.370 27831567 PMC5260898 · DOI
  105. [108]Ede B.C. Asmaro R.R. Moppett J.P. Diamanti P. Blair A. Investigating chemoresistance to improve sensitivity of childhood T-cell acute lymphoblastic leukemia to parthenolide Haematologica 2018 103 1493 1501 10.3324/haematol.2017.186700 29773592 PMC6119138 · DOI
  106. [109]Balandrán J.C. Purizaca J. Enciso J. Dozal D. Sandoval A. Jiménez-Hernández E. Alemán-Lazarini L. Perez-Koldenkova V. Quintela-Núñez Del Prado H. Rios de Los Ríos J. Pro-inflammatory-Related Loss of CXCL12 Niche Promotes Acute Lymphoblastic Leukemic Progression at the Expense of Normal Lymphopoiesis Front. Immunol. 2016 7 666 10.3389/fimmu.2016.00666 28111575 PMC5216624 · DOI
  107. [110]Osman A.E.G. Deininger M.W. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions Blood Rev. 2021 49 100825 10.1016/j.blre.2021.100825 33773846 PMC8563059 · DOI
  108. [111]Spiers A.S. Bain B.J. Turner J.E. The peripheral blood in chronic granulocytic leukaemia. Study of 50 untreated Philadelphia-positive cases Scand. J. Haematol. 1977 18 25 38 10.1111/j.1600-0609.1977.tb01474.x 265093 · DOI
  109. [112]Thiele J. Kvasnicka H.M. Fischer R. Bone marrow histopathology in chronic myelogenous leukemia (CML)—Evaluation of distinctive features with clinical impact Histol. Histopathol. 1999 14 1241 1256 10506940
  110. [113]Faderl S. Talpaz M. Estrov Z. O’Brien S. Kurzrock R. Kantarjian H.M. The biology of chronic myeloid leukemia N. Engl. J. Med. 1999 341 164 172 10.1056/NEJM199907153410306 10403855 · DOI
  111. [114]Rinaldi I. Winston K. Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review J. Blood Med. 2023 14 261 277 10.2147/JBM.S382090 37051025 PMC10084831 · DOI
  112. [115]Eide C.A. O’Hare T. Chronic myeloid leukemia: Advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors Curr. Hematol. Malig. Rep. 2015 10 158 166 10.1007/s11899-015-0248-3 25700679 PMC4447524 · DOI
  113. [116]Mojtahedi H. Yazdanpanah N. Rezaei N. Chronic myeloid leukemia stem cells: Targeting therapeutic implications Stem Cell Res. Ther. 2021 12 603 10.1186/s13287-021-02659-1 34922630 PMC8684082 · DOI
  114. [117]Rea D. Cayuela J.M. Treatment-free remission in patients with chronic myeloid leukemia Int. J. Hematol. 2018 108 355 364 10.1007/s12185-017-2295-0 28689264 · DOI
  115. [118]Jootar S. Pornprasertsud N. Petvises S. Rerkamnuaychoke B. Disthabanchong S. Pakakasama S. Ungkanont A. Hongeng S. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion Leuk. Res. 2006 30 1493 1498 10.1016/j.leukres.2006.04.013 16839603 · DOI
  116. [119]Xishan Z. Guangyu A. Yuguang S. Hongmei Z. The research on the immuno-modulatory defect of mesenchymal stem cell from Chronic Myeloid Leukemia patients J. Exp. Clin. Cancer Res. 2011 30 47 10.1186/1756-9966-30-47 21535879 PMC3095541 · DOI
  117. [120]Tabe Y. Jin L. Iwabuchi K. Wang R.Y. Ichikawa N. Miida T. Cortes J. Andreeff M. Konopleva M. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts Leukemia 2012 26 883 892 10.1038/leu.2011.291 22005789 · DOI
  118. [121]Zhang B. Li M. McDonald T. Holyoake T.L. Moon R.T. Campana D. Shultz L. Bhatia R. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling Blood 2013 121 1824 1838 10.1182/blood-2012-02-412890 23299311 PMC3591802 · DOI
  119. [122]Vianello F. Villanova F. Tisato V. Lymperi S. Ho K.K. Gomes A.R. Marin D. Bonnet D. Apperley J. Lam E.W. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis Haematologica 2010 95 1081 1089 10.3324/haematol.2009.017178 20179085 PMC2895031 · DOI
  120. [123]Weisberg E. Wright R.D. McMillin D.W. Mitsiades C. Ray A. Barrett R. Adamia S. Stone R. Galinsky I. Kung A.L. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Mol. Cancer Ther. 2008 7 1121 1129 10.1158/1535-7163.MCT-07-2331 18445657 PMC4034541 · DOI
  121. [124]Zhang X. Tu H. Yang Y. Jiang X. Hu X. Luo Q. Li J. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway J. Biol. Chem. 2019 294 12167 12179 10.1074/jbc.RA119.008037 31235520 PMC6690703 · DOI
  122. [125]Zuo S. Sun L. Wang Y. Chen B. Wang J. Ge X. Lu Y. Yang N. Shen P. Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy Cell Death Dis. 2021 12 208 10.1038/s41419-021-03499-w 33627636 PMC7904926 · DOI
  123. [126]Giallongo C. Romano A. Parrinello N.L. La Cava P. Brundo M.V. Bramanti V. Stagno F. Vigneri P. Chiarenza A. Palumbo G.A. Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients PLoS ONE 2016 11 e0158392 10.1371/journal.pone.0158392 27391078 PMC4938578 · DOI
  124. [127]Hallek M. Shanafelt T.D. Eichhorst B. Chronic lymphocytic leukaemia Lancet 2018 391 1524 1537 10.1016/S0140-6736(18)30422-7 29477250 · DOI
  125. [128]Scarfò L. Ferreri A.J. Ghia P. Chronic lymphocytic leukaemia Crit. Rev. Oncol. Hematol. 2016 104 169 182 10.1016/j.critrevonc.2016.06.003 27370174 · DOI
  126. [129]Caligaris-Cappio F. Hamblin T.J. B-cell chronic lymphocytic leukemia: A bird of a different feather J. Clin. Oncol. 1999 17 399 408 10.1200/JCO.1999.17.1.399 10458259 · DOI
  127. [130]Arp E.W. Jr. Wolf P.H. Checkoway H. Lymphocytic leukemia and exposures to benzene and other solvents in the rubber industry J. Occup. Med. 1983 25 598 602 6886869
  128. [131]Blair A. White D.W. Leukemia cell types and agricultural practices in Nebraska Arch. Environ. Health 1985 40 211 214 10.1080/00039896.1985.10545920 4051575 · DOI
  129. [132]Brown L.M. Gibson R. Blair A. Burmeister L.F. Schuman L.M. Cantor K.P. Fraumeni J.F. Jr. Smoking and risk of leukemia Am. J. Epidemiol. 1992 135 763 768 10.1093/oxfordjournals.aje.a116362 1595675 · DOI
  130. [133]Khalade A. Jaakkola M.S. Pukkala E. Jaakkola J.J. Exposure to benzene at work and the risk of leukemia: A systematic review and meta-analysis Environ. Health 2010 9 31 10.1186/1476-069X-9-31 20584305 PMC2903550 · DOI
  131. [134]Marwick C. Link found between Agent Orange and chronic lymphocytic leukaemia BMJ 2003 326 242 10.1136/bmj.326.7383.242/d 12560261 PMC1169216 · DOI
  132. [135]Schubauer-Berigan M.K. Daniels R.D. Fleming D.A. Markey A.M. Couch J.R. Ahrenholz S.H. Burphy J.S. Anderson J.L. Tseng C.Y. Chronic lymphocytic leukaemia and radiation: Findings among workers at five US nuclear facilities and a review of the recent literature Br. J. Haematol. 2007 139 799 808 10.1111/j.1365-2141.2007.06843.x 17922878 · DOI
  133. [136]Talibov M. Auvinen A. Weiderpass E. Hansen J. Martinsen J.I. Kjaerheim K. Tryggvadottir L. Pukkala E. Occupational solvent exposure and adult chronic lymphocytic leukemia: No risk in a population-based case-control study in four Nordic countries Int. J. Cancer 2017 141 1140 1147 10.1002/ijc.30814 28571111 · DOI
  134. [137]Dühren-von Minden M. Übelhart R. Schneider D. Wossning T. Bach M.P. Buchner M. Hofmann D. Surova E. Follo M. Köhler F. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling Nature 2012 489 309 312 10.1038/nature11309 22885698 · DOI
  135. [138]Ghia P. Caligaris-Cappio F. Monoclonal B-cell lymphocytosis: Right track or red herring? Blood 2012 119 4358 4362 10.1182/blood-2012-01-404681 22422819 · DOI
  136. [139]Herishanu Y. Katz B.Z. Lipsky A. Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: Clinical and therapeutic implications Hematol. Oncol. Clin. N. Am. 2013 27 173 206 10.1016/j.hoc.2013.01.002 PMC3660068 23561469 · DOI
  137. [140]Sun C. Chen Y.C. Martinez Zurita A. Baptista M.J. Pittaluga S. Liu D. Rosebrock D. Gohil S.H. Saba N.S. Davies-Hill T. The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia Blood Adv. 2023 7 145 158 10.1182/bloodadvances.2021006941 35358998 PMC9811214 · DOI
  138. [141]Dubois N. Crompot E. Meuleman N. Bron D. Lagneaux L. Stamatopoulos B. Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles Front. Oncol. 2020 10 1422 10.3389/fonc.2020.01422 32974152 PMC7466743 · DOI
  139. [142]Binder M. Léchenne B. Ummanni R. Scharf C. Balabanov S. Trusch M. Schlüter H. Braren I. Spillner E. Trepel M. Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells PLoS ONE 2010 5 e15992 10.1371/journal.pone.0015992 21209908 PMC3012720 · DOI
  140. [143]Trimarco V. Ave E. Facco M. Chiodin G. Frezzato F. Martini V. Gattazzo C. Lessi F. Giorgi C.A. Visentin A. Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): Implications for neoplastic cell survival Oncotarget 2015 6 42130 42149 10.18632/oncotarget.6239 26517523 PMC4747215 · DOI
  141. [144]Plander M. Ugocsai P. Seegers S. Orsó E. Reichle A. Schmitz G. Hofstädter F. Brockhoff G. Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma Ann. Hematol. 2011 90 1381 1390 10.1007/s00277-011-1218-z 21465189 · DOI
  142. [145]Ding W. Nowakowski G.S. Knox T.R. Boysen J.C. Maas M.L. Schwager S.M. Wu W. Wellik L.E. Dietz A.B. Ghosh A.K. Bi-directional activation between mesenchymal stem cells and CLL B-cells: Implication for CLL disease progression Br. J. Haematol. 2009 147 471 483 10.1111/j.1365-2141.2009.07868.x 19751240 PMC2783570 · DOI
  143. [146]Yang Y. Li J. Geng Y. Exosomes derived from chronic lymphocytic leukaemia cells transfer miR-146a to induce the transition of mesenchymal stromal cells into cancer-associated fibroblasts J. Biochem. 2020 168 491 498 10.1093/jb/mvaa064 32770182 · DOI
  144. [147]Ding W. Knox T.R. Tschumper R.C. Wu W. Schwager S.M. Boysen J.C. Jelinek D.F. Kay N.E. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: Implications for an angiogenic switch Blood 2010 116 2984 2993 10.1182/blood-2010-02-269894 20606160 PMC2974606 · DOI
  145. [148]Ding D.C. Shyu W.C. Lin S.Z. Mesenchymal stem cells Cell Transplant. 2011 20 5 14 10.3727/096368910X 21396235 · DOI
  146. [149]Noronha N.C. Mizukami A. Caliári-Oliveira C. Cominal J.G. Rocha J.L.M. Covas D.T. Swiech K. Malmegrim K.C.R. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies Stem Cell Res. Ther. 2019 10 131 10.1186/s13287-019-1224-y 31046833 PMC6498654 · DOI · Paper page
  147. [150]Wu X. Jiang J. Gu Z. Zhang J. Chen Y. Liu X. Mesenchymal stromal cell therapies: Immunomodulatory properties and clinical progress Stem Cell Res. Ther. 2020 11 345 10.1186/s13287-020-01855-9 32771052 PMC7414268 · DOI · Paper page
  148. [151]Studeny M. Marini F.C. Dembinski J.L. Zompetta C. Cabreira-Hansen M. Bekele B.N. Champlin R.E. Andreeff M. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents J. Natl. Cancer Inst. 2004 96 1593 1603 10.1093/jnci/djh299 15523088 · DOI
  149. [152]Duchi S. Sotgiu G. Lucarelli E. Ballestri M. Dozza B. Santi S. Guerrini A. Dambruoso P. Giannini S. Donati D. Mesenchymal stem cells as delivery vehicle of porphyrin loaded nanoparticles: Effective photoinduced in vitro killing of osteosarcoma J. Control Release 2013 168 225 237 10.1016/j.jconrel.2013.03.012 23524189 · DOI
  150. [153]Huang B. Tabata Y. Gao J.Q. Mesenchymal stem cells as therapeutic agents and potential targeted gene delivery vehicle for brain diseases J. Control Release 2012 162 464 473 10.1016/j.jconrel.2012.07.034 22885026 · DOI
  151. [154]Gao Z. Zhang L. Hu J. Sun Y. Mesenchymal stem cells: A potential targeted-delivery vehicle for anti-cancer drug, loaded nanoparticles Nanomedicine 2013 9 174 184 10.1016/j.nano.2012.06.003 22772046 · DOI
  152. [155]Porada C.D. Almeida-Porada G. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery Adv. Drug Deliv. Rev. 2010 62 1156 1166 10.1016/j.addr.2010.08.010 20828588 PMC2991625 · DOI
  153. [156]Von Bahr L. Sundberg B. Lönnies L. Sander B. Karbach H. Hägglund H. Ljungman P. Gustafsson B. Karlsson H. Le Blanc K. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy Biol. Blood Marrow Transplant. 2012 18 557 564 10.1016/j.bbmt.2011.07.023 21820393 · DOI
  154. [157]Kadri N. Amu S. Iacobaeus E. Boberg E. Le Blanc K. Current perspectives on mesenchymal stromal cell therapy for graft versus host disease Cell Mol. Immunol. 2023 20 613 625 10.1038/s41423-023-01022-z 37165014 PMC10229573 · DOI
  155. [158]Zhao K. Liu Q. The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation J. Hematol. Oncol. 2016 9 46 10.1186/s13045-016-0276-z 27193054 PMC4870746 · DOI
  156. [160]Neuhuber B. Swanger S.A. Howard L. Mackay A. Fischer I. Effects of plating density and culture time on bone marrow stromal cell characteristics Exp. Hematol. 2008 36 1176 1185 10.1016/j.exphem.2008.03.019 18495329 PMC2603339 · DOI
  157. [161]Ho A.D. Wagner W. Franke W. Heterogeneity of mesenchymal stromal cell preparations Cytotherapy 2008 10 320 330 10.1080/14653240802217011 18574765 · DOI
  158. [162]Yang X. Du J. Xu X. Xu C. Song W. IFN-γ-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway J. Immunol. Res. 2014 2014 318098 10.1155/2014/318098 24971369 PMC4058226 · DOI · Paper page
  159. [163]Li X. Lu Y. Huang W. Xu H. Chen X. Geng Q. Fan H. Tan Y. Xue G. Jiang X. In Vitro effect of adenovirus-mediated human Gamma Interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia Hematol. Oncol. 2006 24 151 158 10.1002/hon.779 16700092 · DOI · Paper page
  160. [165]Zhang X. Zhang L. Xu W. Qian H. Ye S. Zhu W. Cao H. Yan Y. Li W. Wang M. Experimental therapy for lung cancer: Umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery Curr. Cancer Drug Targets 2013 13 92 102 10.2174/156800913804486665 23170786 · DOI
  161. [166]Gangadaran P. Rajendran R.L. Lee H.W. Kalimuthu S. Hong C.M. Jeong S.Y. Lee S.W. Lee J. Ahn B.C. Extracellular vesicles from mesenchymal stem cells activates VEGF receptors and accelerates recovery of hindlimb ischemia J. Control Release 2017 264 112 126 10.1016/j.jconrel.2017.08.022 28837823 · DOI
  162. [167]Rajendran R.L. Gangadaran P. Bak S.S. Oh J.M. Kalimuthu S. Lee H.W. Baek S.H. Zhu L. Sung Y.K. Jeong S.Y. Extracellular vesicles derived from MSCs activates dermal papilla cell in vitro and promotes hair follicle conversion from telogen to anagen in mice Sci. Rep. 2017 7 15560 10.1038/s41598-017-15505-3 29138430 PMC5686117 · DOI
  163. [168]Hendijani F. Javanmard S.H. Sadeghi-aliabadi H. Human Wharton’s jelly mesenchymal stem cell secretome display antiproliferative effect on leukemia cell line and produce additive cytotoxic effect in combination with doxorubicin Tissue Cell 2015 47 229 234 10.1016/j.tice.2015.01.005 25779671 · DOI
  164. [169]Rumpel M. Friedrich T. Deininger M.W. Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase Blood 2003 101 4641 4643 10.1182/blood-2003-02-0481 12756164 · DOI
  165. [170]Otsu K. Das S. Houser S.D. Quadri S.K. Bhattacharya S. Bhattacharya J. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells Blood 2009 113 4197 4205 10.1182/blood-2008-09-176198 19036701 PMC2676081 · DOI
  166. [171]Sauer H. Wartenberg M. Reactive oxygen species as signaling molecules in cardiovascular differentiation of embryonic stem cells and tumor-induced angiogenesis Antioxid. Redox Signal 2005 7 1423 1434 10.1089/ars.2005.7.1423 16356105 · DOI
  167. [172]Song N. Gao L. Qiu H. Huang C. Cheng H. Zhou H. Lv S. Chen L. Wang J. Mouse bone marrow-derived mesenchymal stem cells inhibit leukemia/lymphoma cell proliferation in vitro and in a mouse model of allogeneic bone marrow transplant Int. J. Mol. Med. 2015 36 139 149 10.3892/ijmm.2015.2191 25901937 PMC4494598 · DOI
  168. [173]Ramasamy R. Lam E.W. Soeiro I. Tisato V. Bonnet D. Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: Impact on in vivo tumor growth Leukemia 2007 21 304 310 10.1038/sj.leu.2404489 17170725 · DOI · Paper page
  169. [174]Han Y. Wang Y. Xu Z. Li J. Yang J. Li Y. Shang Y. Luo J. Effect of bone marrow mesenchymal stem cells from blastic phase chronic myelogenous leukemia on the growth and apoptosis of leukemia cells Oncol. Rep. 2013 30 1007 1013 10.3892/or.2013.2518 23733230 · DOI
  170. [175]Sarmadi V.H. Tong C.K. Vidyadaran S. Abdullah M. Seow H.F. Ramasamy R. Mesenchymal stem cells inhibit proliferation of lymphoid origin haematopoietic tumour cells by inducing cell cycle arrest Med. J. Malaysia 2010 65 209 214 21939170
  171. [176]Wei Z. Chen N. Guo H. Wang X. Xu F. Ren Q. Lu S. Liu B. Zhang L. Zhao H. Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells J. Exp. Clin. Cancer Res. 2009 28 141 10.1186/1756-9966-28-141 19883517 PMC2779804 · DOI
  172. [177]Tian K. Yang S. Ren Q. Han Z. Lu S. Ma F. Zhang L. Han Z. p38 MAPK contributes to the growth inhibition of leukemic tumor cells mediated by human umbilical cord mesenchymal stem cells Cell Physiol. Biochem. 2010 26 799 808 10.1159/000323973 21220911 · DOI
  173. [178]Kastan M.B. Bartek J. Cell-cycle checkpoints and cancer Nature 2004 432 316 323 10.1038/nature03097 15549093 · DOI · Paper page
  174. [179]Uy G.L. Rettig M.P. Motabi I.H. McFarland K. Trinkaus K.M. Hladnik L.M. Kulkarni S. Abboud C.N. Cashen A.F. Stockerl-Goldstein K.E. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia Blood 2012 119 3917 3924 10.1182/blood-2011-10-383406 22308295 PMC3350358 · DOI
  175. [180]Borthakur G. Zeng Z. Cortes J.E. Chen H.C. Huang X. Konopleva M. Ravandi F. Kadia T. Patel K.P. Daver N. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients Am. J. Hematol. 2020 95 1296 1303 10.1002/ajh.25943 32697348 · DOI
  176. [181]Zhou H. Mak P.Y. Mu H. Mak D.H. Zeng Z. Cortes J. Liu Q. Andreeff M. Carter B.Z. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo Leukemia 2017 31 2065 2074 10.1038/leu.2017.87 28321124 PMC5628102 · DOI
  177. [182]Jiang X. Mak P.Y. Mu H. Tao W. Mak D.H. Kornblau S. Zhang Q. Ruvolo P. Burks J.K. Zhang W. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia Clin. Cancer Res. 2018 24 2417 2429 10.1158/1078-0432.CCR-17-1556 29463558 PMC5955840 · DOI
  178. [183]Carter B.Z. Mak P.Y. Wang X. Tao W. Ruvolo V. Mak D. Mu H. Burks J.K. Andreeff M. An ARC-Regulated IL1β/Cox-2/PGE2/β-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML Cancer Res. 2019 79 1165 1177 10.1158/0008-5472.CAN-18-0921 30674535 PMC6420856 · DOI
  179. [184]Lee J.H. Faderl S. Pagel J.M. Jung C.W. Yoon S.S. Pardanani A.D. Becker P.S. Lee H. Choi J. Lee K. Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome Blood Adv. 2020 4 2032 2043 10.1182/bloodadvances.2019000757 32396615 PMC7218422 · DOI
  180. [185]Gutjahr J.C. Bayer E. Yu X. Laufer J.M. Höpner J.P. Tesanovic S. Härzschel A. Auer G. Rieß T. Salmhofer A. CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity Haematologica 2021 106 2102 2113 10.3324/haematol.2019.231944 32616529 PMC8327716 · DOI
  181. [186]Yu X. Munoz-Sagredo L. Streule K. Muschong P. Bayer E. Walter R.J. Gutjahr J.C. Greil R. Concha M.L. Müller-Tidow C. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues Blood 2021 138 1067 1080 10.1182/blood.2020006343 34115113 · DOI
  182. [187]DeAngelo D.J. Jonas B.A. Liesveld J.L. Bixby D.L. Advani A.S. Marlton P. Magnani J.L. Thackray H.M. Feldman E.J. O’Dwyer M.E. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia Blood 2022 139 1135 1146 10.1182/blood.2021010721 34543383 · DOI
  183. [188]Berdeja J.G. Hart L.L. Mace J.R. Arrowsmith E.R. Essell J.H. Owera R.S. Hainsworth J.D. Flinn I.W. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma Haematologica 2015 100 670 676 10.3324/haematol.2014.119735 25710456 PMC4420216 · DOI
  184. [189]Advani A.S. Cooper B. Visconte V. Elson P. Chan R. Carew J. Wei W. Mukherjee S. Gerds A. Carraway H. A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia Clin. Cancer Res. 2019 25 4231 4237 10.1158/1078-0432.CCR-18-3886 30992301 PMC6635077 · DOI
  185. [190]Wong R.S. Mesenchymal stem cells: Angels or demons? J. Biomed. Biotechnol. 2011 2011 459510 10.1155/2011/459510 21822372 PMC3142786 · DOI
  186. [192]Tian L.L. Yue W. Zhu F. Li S. Li W. Human mesenchymal stem cells play a dual role on tumor cell growth in vitro and in vivo J. Cell Physiol. 2011 226 1860 1867 21442622
  187. [193]Kidd S. Caldwell L. Dietrich M. Samudio I. Spaeth E.L. Watson K. Shi Y. Abbruzzese J. Konopleva M. Andreeff M. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment Cytotherapy 2010 12 615 625 10.3109/14653241003631815 20230221 · DOI
  188. [194]Yu J.M. Jun E.S. Bae Y.C. Jung J.S. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo Stem Cells Dev. 2008 17 463 473 10.1089/scd.2007.0181 18522494 · DOI
  189. [195]Lin G. Yang R. Banie L. Wang G. Ning H. Li L.C. Lue T.F. Lin C.S. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor Prostate 2010 70 1066 1073 10.1002/pros.21140 20232361 PMC2877148 · DOI
  190. [196]Zhu N. Wang H. Wei J. Wang B. Shan W. Lai X. Zhao Y. Yu J. Huang H. NR2F2 regulates bone marrow-derived mesenchymal stem cell-promoted proliferation of Reh cells Mol. Med. Rep. 2016 14 1351 1356 10.3892/mmr.2016.5389 27314877 · DOI
  191. [197]Lin H.D. Fong C.Y. Biswas A. Choolani M. Bongso A. Human Umbilical Cord Wharton’s Jelly Stem Cell Conditioned Medium Induces Tumoricidal Effects on Lymphoma Cells through Hydrogen Peroxide Mediation J. Cell Biochem. 2016 117 2045 2055 10.1002/jcb.25501 27392313 · DOI
  192. [198]Ball S.G. Shuttleworth C.A. Kielty C.M. Mesenchymal stem cells and neovascularization: Role of platelet-derived growth factor receptors J. Cell Mol. Med. 2007 11 1012 1030 10.1111/j.1582-4934.2007.00120.x 17979880 PMC4401270 · DOI
  193. [199]Al-Khaldi A. Eliopoulos N. Martineau D. Lejeune L. Lachapelle K. Galipeau J. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo Gene Ther. 2003 10 621 629 10.1038/sj.gt.3301934 12692590 · DOI
  194. [200]Roorda B.D. ter Elst A. Kamps W.A. de Bont E.S. Bone marrow-derived cells and tumor growth: Contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells Crit. Rev. Oncol. Hematol. 2009 69 187 198 10.1016/j.critrevonc.2008.06.004 18675551 · DOI
  195. [201]Liu Y. Han Z.P. Zhang S.S. Jing Y.Y. Bu X.X. Wang C.Y. Sun K. Jiang G.C. Zhao X. Li R. Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer J. Biol. Chem. 2011 286 25007 25015 10.1074/jbc.M110.213108 21592963 PMC3137074 · DOI
  196. [202]Castro-Manrreza M.E. Montesinos J.J. Immunoregulation by mesenchymal stem cells: Biological aspects and clinical applications J. Immunol. Res. 2015 2015 394917 10.1155/2015/394917 25961059 PMC4417567 · DOI
  197. [203]Di Ianni M. Del Papa B. De Ioanni M. Moretti L. Bonifacio E. Cecchini D. Sportoletti P. Falzetti F. Tabilio A. Mesenchymal cells recruit and regulate T regulatory cells Exp. Hematol. 2008 36 309 318 10.1016/j.exphem.2007.11.007 18279718 · DOI
  198. [204]Sotiropoulou P.A. Perez S.A. Gritzapis A.D. Baxevanis C.N. Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells Stem Cells 2006 24 74 85 10.1634/stemcells.2004-0359 16099998 · DOI · Paper page
  199. [205]Potenta S. Zeisberg E. Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression Br. J. Cancer 2008 99 1375 1379 10.1038/sj.bjc.6604662 18797460 PMC2579683 · DOI
  200. [206]Thiery J.P. Epithelial-mesenchymal transitions in tumour progression Nat. Rev. Cancer 2002 2 442 454 10.1038/nrc822 12189386 · DOI

200 of 214 shown

Cited by

Sorted by citations

Authors
Wu, C.-H., Weng, T.-F., Li, J.-P., & Wu, K.-H.
Affiliations
  • National Defense Medical Center (TW)
  • Chung Shan Medical University Hospital (TW)
Corresponding author
  • Li, Ju-Pi
  • Wu, Kang-Hsi
ORCID
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2024-02-21
Volume
25
Issue
5
Pages
2527
ISSN
1422-0067 (ISSN-L)
DOI
10.3390/ijms25052527
PMC
PMC10932140
OpenAlex
W4392016885
Cited by
13
References
6
Citations by year
2026: 6 · 2025: 5 · 2024: 2
FWCI
0.99
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
mesenchymal stem cells, leukemia, bone marrow microenvironment, hematopoietic stem cells, acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, treatment resistance, chemoresistance, hematopoietic stem cell transplantation, anticancer activity, hematologic malignancies
MeSH terms
Biology, Hematopoietic Stem Cells, Humans, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Tumor Microenvironment, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review